NCT06538935 is a Phase 2 clinical trial of adbelimumab in Hepatocellular Carcinoma, sponsored by Fujian Cancer Hospital.

Who is sponsoring NCT06538935?

NCT06538935 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT06538935?

Interventions in NCT06538935: adbelimumab, SBRT, apatinib.

What condition does NCT06538935 study?

NCT06538935 studies Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade, Tyrosine Kinase Inhibitor.

Is NCT06538935 still recruiting?

NCT06538935 is currently not yet recruiting. Last updated 5 August 2024.

Last reviewed 2024-08-05 · How we verify

NCT06538935

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II, Open-label, Two Arm, Investigator-initiated Trail of Stereotactic Radiotherapy (SBRT) in Combination With an Anti-PD-L1 Inhibitor Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Not yet recruiting Phase 2 Last updated 5 August 2024

What this trial tests

Phase 2 trial testing adbelimumab in Hepatocellular Carcinoma in 80 participants. Not yet recruiting.

Timeline

1 January 2025

Primary endpoint
1 December 2026

1 December 2027

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 January 2025
Primary completion	1 December 2026
Estimated completion	1 December 2027

Drugs / interventions tested

adbelimumab — full drug profile →
SBRT — full drug profile →
apatinib (Apatinib) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
SBRT — all drugs for SBRT →
Immune Checkpoint Blockade — all drugs for Immune Checkpoint Blockade →
Tyrosine Kinase Inhibitor — all drugs for Tyrosine Kinase Inhibitor →

Sponsor

Fujian Cancer Hospital

Who can join

18 and older, any sex, with Hepatocellular Carcinoma or SBRT. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pathological complete response Rate (Perioperative cohort)
Time frame: 4 months
No histologic evidence of malignancy or only the ingredients of carcinoma in situ was found in primary tumors
Objective Response (Conversion cohort)
Time frame: 12 months
It is defined as the proportion of patients whose tumors shrink to a predetermined size and maintain a minimum time limit. It includes the cases of CR and PR.

Sponsor's own description

This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in Combination With Adbelimumab and Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy of SBRT in Combination With Adbelimumab and Apatinib as a preoperative and conversion treatment of HCC.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The role of immunotherapy prior to liver transplantation in advanced or down-staged HCC - timing of transplants, selection of patients, and hurdles to overcome with immunosuppression.
Tabrizian P, Chan A, Marino R, Giudicelli H, et al · · 2026 · PMID 41186530 · DOI 10.1097/js9.0000000000003520

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06538935 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 5 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06538935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing